Why This Will Make Telehealth Harder to Scale
When the U.S. Food and Drug Administration starts reviewing multiple peptides at once, it’s easy to read it as a growth signal.
More treatments become viable. More clinics start offering them and demand increases. As soon as access becomes easier, competition increases faster than demand.
That’s what we saw with GLP-1s. Early on, some telehealth brands were acquiring customers in the $80–$150 range. Within a year, that same acquisition cost pushed past $250, and in many cases, over $400–$600 as more advertisers entered the space.
At the same time, conversion rates didn’t improve to offset that increase. Across telehealth funnels we’ve reviewed, most landing pages still convert between 2% and 4%. Only a small percentage break past 8–10%. That gap matters.
If your costs double and your conversion rate stays the same, your business doesn’t slow down. It becomes unprofitable.
That’s why this peptide shift matters. It doesn’t just create opportunity. It raises the bar for what it takes to compete.
The Real Constraint Isn’t Supply. It’s Trust.
As categories mature, the bottleneck shifts.
Early on, the constraint is access. Can you even get the treatment? Later, the constraint becomes trust. Who do you choose?
This is where most telehealth brands fall behind. They optimize for availability instead of understanding.
But the data is clear:
- 70%+ of health consumers say they need to “fully understand a treatment” before purchasing (Pew Research)
- Over 60% of users abandon healthcare forms due to complexity or lack of clarity mid-process
- Brands that include clear expectations and timelines in their onboarding flows see up to 20–30% higher completion rates
In other words, the brand that explains better converts better. Not the one with the most products.
What Actually Drives Growth in This Phase
1. Clear Positioning Beats Broad Offerings
When everything looks similar, specificity wins.
The highest-converting telehealth brands don’t try to serve everyone. They narrow their message until it’s obvious who the product is for.
Instead of offering “peptides for health optimization,” they anchor around a single outcome:
- Weight loss for women over 40
- Cognitive support for high-performance professionals
- Recovery protocols for athletes
That level of clarity reduces cognitive load and increases conversion. In tests we’ve run, narrowing the target audience and rewriting messaging accordingly improved conversion rates by 30–60% without any change in traffic.
2. Conversion Rate Becomes the Primary Lever
Most brands still treat traffic as the growth engine.
It’s not. Conversion is.
If you’re paying $60 per click and converting at 2%, you’re acquiring customers at $3,000. If you increase conversion to 6%, that drops to $1,000 without touching your ad spend.
That’s the difference between scaling and stalling.
Across telehealth funnels, the biggest leaks are consistent:
- 40–60% of users bounce on the landing page
- 30–50% abandon intake forms midway
- 10–20% don’t complete payment after consult
Each step compounds inefficiency.
Fixing even one of these stages has more impact than increasing traffic by 50%.
3. Education Is the New Acquisition Channel
Peptides are still poorly understood by the average consumer. That’s not a disadvantage. It’s leverage.
Brands that invest in explaining:
- What the peptide does
- What results actually look like over time
- What risks or limitations exist
consistently outperform those that rely on vague claims.
We’ve seen educational landing pages outperform product-first pages by 20–35% in conversion rate when the category is complex or unfamiliar.
Clarity reduces hesitation. And hesitation is what kills conversion.
4. Retention Determines Whether You Survive Rising CAC
Acquisition gets harder as competition increases. That’s predictable. What’s less discussed is how retention offsets that.
In subscription-based telehealth models, a 20% increase in retention can improve LTV by 30–50%. That gives you more room to absorb rising CAC without sacrificing profitability. But most brands don’t build for this.
They focus on the first purchase, then lose the customer due to lack of guidance, unclear expectations, or poor follow-up. The brands that scale in competitive markets don’t just acquire users. They manage the experience after the sale.
What This Means Going Into 2026
This isn’t a slow shift. It’s already happening.
Telehealth continues to grow at an estimated 20–25% annually, and peptides are adding another layer of competition on top of that growth.
As access expands, expect three things to happen simultaneously:
- Acquisition costs increase across paid channels
- Conversion rates become the primary constraint on growth
- Brand trust becomes the deciding factor in purchase decisions
That combination creates pressure. Brands that relied on early demand or simple funnels won’t hold performance. Brands that invest in clarity, conversion, and retention will.
Bottom Line
The FDA reviewing peptides isn’t just a regulatory update. It’s a signal that this category is about to get more competitive, more crowded, and less forgiving. More brands will enter, more offers will look the same, more pressure will be placed on performance.
The brands that win won’t be the ones that move the fastest or launch the most products. They’ll be the ones that make the clearest case for why they should be chosen, convert efficiently at every stage of the funnel, and build enough trust to keep customers long after the first purchase.
If you’re thinking about adding peptides, don’t start with product - start with positioning. Because when the market fills up, growth doesn’t come from doing more. It comes from making your the value of your offer clear.
